Structural biology spin-out tackles major diseases

Aug 07, 2008

A spin out company from basic structural biology, Asterion Ltd., has led to new technology that provides a way of creating therapeutic proteins to tackle major diseases such as cancer, diabetes and infertility. The research was carried out at the University of Sheffield in laboratories supported by the Biotechnology and Biological Sciences Research Council (BBSRC). This work is reported in the current edition of BBSRC Business, the quarterly research highlights magazine of the Biotechnology and Biological Sciences Research Council.

Professor Richard Ross, Chief Scientific Officer of Asterion Ltd., said: "A big challenge for biological therapeutics is that they are broken down rapidly in the body. The technology developed by Asterion Ltd. is based on basic structural biology work that has provided us with the knowledge necessary to develop longer acting drugs. This is a major advantage for patients, as it means monthly injections rather than daily injections."

Professor Ross, along with fellow founding directors Professors Pete Artymiuk and Jon Sayers have shown that it is possible to engineer proteins that can intervene when there is a deficiency in hormones. Their initial experiments involved fusing different elements of hormone and receptor in order to treat a growth disorders such as short stature (a deficiency in growth hormone).

Professor Ross continued: "Our patented and versatile therapeutic platform technology ProFuse TM, could also tackle major diseases such as some cancers, anaemia, infertility and diabetes. Under normal circumstances hormones of the type known as cytokine hormones - growth hormone for example - circulate in the blood and are bound to proteins that prevent them from being degraded. The basic structural biology work we have done in the past means that we can see the interaction between the hormone and the binding protein in exquisite detail. Our understanding of this structural information means that we can rationally design drugs that consist of this pairing of hormone and binding protein that still allows them to activate the cell surface receptor. In this situation, the hormone portion of the drug is better protected in the circulation from degradation and so it has a much longer effective life in the body."

This system of drug design has been developed by Asterion Ltd. into a patented and versatile therapeutic platform technology called ProFuse™. Using this technology it will be possible to make other useful pairings between therapeutic hormones and protective receptor domains (the binding proteins) that could be used to tackle major diseases such as some cancers, anaemia, infertility and diabetes.

Source: Biotechnology and Biological Sciences Research Council

Explore further: Diabetes drug found in freshwater is a potential cause of intersex fish

Related Stories

Malaria transmission linked to mosquitoes' sexual biology

Feb 26, 2015

Sexual biology may be the key to uncovering why Anopheles mosquitoes are unique in their ability to transmit malaria to humans, according to researchers at Harvard T. H. Chan School of Public Health and University of Per ...

Scientists find key to vitamin A metabolism

Dec 10, 2014

Researchers at Case Western Reserve University School of Medicine have uncovered the mechanism that enables the enzyme Lecithin: retinol acyltransferase (LRAT) to store vitamin A—a process that is indispensable ...

When stressed birds fly the nest

Oct 29, 2014

Stress in young birds makes them leave home early and occupy more central social network positions later in life, according to the latest research published today by scientists at the Universities of St Andrews ...

How steroid hormones enable plants to grow

Aug 19, 2014

Plants can adapt extremely quickly to changes in their environment. Hormones, chemical messengers that are activated in direct response to light and temperature stimuli help them achieve this. Plant steroid ...

Recommended for you

York's anti-malarial plant given Chinese approval

Apr 24, 2015

A new hybrid plant used in anti-malarial drug production, developed by scientists at the University of York's Centre for Novel Agricultural Products (CNAP), is now registered as a new variety in China.

The appeal of being anti-GMO

Apr 24, 2015

A team of Belgian philosophers and plant biotechnologists have turned to cognitive science to explain why opposition to genetically modified organisms (GMOs) has become so widespread, despite positive contributions ...

Micro fingers for arranging single cells

Apr 24, 2015

Functional analysis of a cell, which is the fundamental unit of life, is important for gaining new insights into medical and pharmaceutical fields. For efficiently studying cell functions, it is essential ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.